178 related articles for article (PubMed ID: 32122255)
1.
Kim M; Kim SJ; Xu Z; Ha SY; Byeon JH; Kang EJ; Shin SH; Yoo SK; Jee HG; Yoon SG; Yi JW; Bae JM; Yu HW; Chai YJ; Cho SW; Choi JY; Lee KE; Han W
Thyroid; 2020 Apr; 30(4):487-500. PubMed ID: 32122255
[No Abstract] [Full Text] [Related]
2. Expression Profiling of a Human Thyroid Cell Line Stably Expressing the BRAFV600E Mutation.
Kim BA; Jee HG; Yi JW; Kim SJ; Chai YJ; Choi JY; Lee KE
Cancer Genomics Proteomics; 2017 Jan; 14(1):53-67. PubMed ID: 28031237
[TBL] [Abstract][Full Text] [Related]
3. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
[TBL] [Abstract][Full Text] [Related]
4. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
Zhang T; Shen X; Liu R; Zhu G; Bishop J; Xing M
Oncotarget; 2017 Jan; 8(1):900-914. PubMed ID: 27863429
[TBL] [Abstract][Full Text] [Related]
5. Targeting miR-31 represses tumourigenesis and dedifferentiation of BRAF
Zhang P; Guan L; Sun W; Zhang Y; Du Y; Yuan S; Cao X; Yu Z; Jia Q; Zheng X; Meng Z; Li X; Zhao L
Clin Transl Med; 2024 May; 14(5):e1694. PubMed ID: 38797942
[TBL] [Abstract][Full Text] [Related]
6. Fine-Tuning Lipid Metabolism by Targeting Mitochondria-Associated Acetyl-CoA-Carboxylase 2 in
Valvo V; Iesato A; Kavanagh TR; Priolo C; Zsengeller Z; Pontecorvi A; Stillman IE; Burke SD; Liu X; Nucera C
Thyroid; 2021 Sep; 31(9):1335-1358. PubMed ID: 33107403
[No Abstract] [Full Text] [Related]
7. An in vivo mouse model of metastatic human thyroid cancer.
Zhang L; Gaskins K; Yu Z; Xiong Y; Merino MJ; Kebebew E
Thyroid; 2014 Apr; 24(4):695-704. PubMed ID: 24262022
[TBL] [Abstract][Full Text] [Related]
8. Acceleration of BRAF
Shimamura M; Kurashige T; Kuatov R; Nakashima M; Nagayama Y
Endocrine; 2020 Sep; 69(3):571-577. PubMed ID: 32281047
[TBL] [Abstract][Full Text] [Related]
9. Key candidate genes associated with BRAF
Yu X; Zhong P; Han Y; Huang Q; Wang J; Jia C; Lv Z
J Cell Physiol; 2019 Dec; 234(12):23369-23378. PubMed ID: 31161615
[TBL] [Abstract][Full Text] [Related]
10. Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.
Mitsiades CS; Negri J; McMullan C; McMillin DW; Sozopoulos E; Fanourakis G; Voutsinas G; Tseleni-Balafouta S; Poulaki V; Batt D; Mitsiades N
Mol Cancer Ther; 2007 Mar; 6(3):1070-8. PubMed ID: 17363500
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
Lee MH; Lee SE; Kim DW; Ryu MJ; Kim SJ; Kim SJ; Kim YK; Park JH; Kweon GR; Kim JM; Lee JU; De Falco V; Jo YS; Shong M
J Clin Endocrinol Metab; 2011 Jan; 96(1):E19-30. PubMed ID: 20926530
[TBL] [Abstract][Full Text] [Related]
12. Role of BRAFV600E in the first preclinical model of multifocal infiltrating myopericytoma development and microenvironment.
Sadow PM; Priolo C; Nanni S; Karreth FA; Duquette M; Martinelli R; Husain A; Clohessy J; Kutzner H; Mentzel T; Carman CV; Farsetti A; Henske EP; Palescandolo E; Macconaill LE; Chung S; Fadda G; Lombardi CP; De Angelis AM; Durante O; Parker JA; Pontecorvi A; Dvorak HF; Fletcher C; Pandolfi PP; Lawler J; Nucera C
J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25063326
[TBL] [Abstract][Full Text] [Related]
13. Inhibiting BRAF Oncogene-Mediated Radioresistance Effectively Radiosensitizes BRAF
Robb R; Yang L; Shen C; Wolfe AR; Webb A; Zhang X; Vedaie M; Saji M; Jhiang S; Ringel MD; Williams TM
Clin Cancer Res; 2019 Aug; 25(15):4749-4760. PubMed ID: 31097454
[TBL] [Abstract][Full Text] [Related]
14. The synergic effect of BRAF
Qu HJ; Qu XY; Hu Z; Lin Y; Wang JR; Zheng CF; Tan Z
Endocr J; 2018 Jan; 65(1):113-120. PubMed ID: 29070763
[TBL] [Abstract][Full Text] [Related]
15. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
[TBL] [Abstract][Full Text] [Related]
16. Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells.
Mitsutake N; Knauf JA; Mitsutake S; Mesa C; Zhang L; Fagin JA
Cancer Res; 2005 Mar; 65(6):2465-73. PubMed ID: 15781663
[TBL] [Abstract][Full Text] [Related]
17. Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.
Nucera C; Nehs MA; Nagarkatti SS; Sadow PM; Mekel M; Fischer AH; Lin PS; Bollag GE; Lawler J; Hodin RA; Parangi S
Oncologist; 2011; 16(3):296-309. PubMed ID: 21355020
[TBL] [Abstract][Full Text] [Related]
18. Induction of the BRAFV600E Mutation in Thyroid Cells Leads to Frequent Hypermethylation.
Yi JW; Ha SY; Jee HG; Kim K; Kim SJ; Chai YJ; Choi JY; Lee KE
Clin Exp Otorhinolaryngol; 2022 Aug; 15(3):273-282. PubMed ID: 35538718
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive Transcriptomic and Genomic Profiling of Subtypes of Follicular Variant of Papillary Thyroid Carcinoma.
Song YS; Won JK; Yoo SK; Jung KC; Kim MJ; Kim SJ; Cho SW; Lee KE; Yi KH; Seo JS; Park YJ
Thyroid; 2018 Nov; 28(11):1468-1478. PubMed ID: 30226444
[TBL] [Abstract][Full Text] [Related]
20. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
Huang Y; Liao D; Pan L; Ye R; Li X; Wang S; Ye C; Chen L
Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
